NDA 207695 · Anacor Pharms INC
Eucrisa
Crisaborole · Topical · Phosphodiesterase 4 Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Apr 3, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Dec 14, 2016
Approved uses
3
Original approval plus efficacy supplements
Registered trials
46
10 Phase 3, 1 recruiting
FAERS reports
9,605
734 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 23, 2025.
EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. EUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. ( 1 )
Mechanism: Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 3, 2023 Supplement 12 · Efficacy LetterLabel
- Mar 23, 2020 Supplement 10 · Efficacy · priority review LabelLetter
- Dec 14, 2016 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
- EUCRISA · CRISABOROLE 2% · OINTMENT, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Crisaborole" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02118792 · 764 participants · Start Mar 2014 · Primary completion Apr 2015
Drug: AN2728 Topical Ointment, 2%; Matching vehicle control · For: Dermatitis, Atopic
Sites: Henrico, Virginia
- Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02118766 · 763 participants · Start Mar 2014 · Primary completion Apr 2015
Drug: AN2728 Topical Ointment, 2%; Matching vehicle control · For: Dermatitis, Atopic
Sites: Stockbridge, Georgia
- A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04040192 · 620 participants · Start Sep 12, 2019 · Primary completion Jan 19, 2022
Drug: Crisaborole 2%; Vehicle · For: Atopic Dermatitis
Sites: Fountain Valley, California; Fremont, California; Colorado Springs, Colorado · 44 sites in all
- Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04360187 · 391 participants · Start Jul 27, 2020 · Primary completion Sep 8, 2021
Drug: Crisaborole Ointment; Crisaborole Placebo Vehicle · For: Atopic Dermatitis
Sites: Beijing, China; Guangzhou, China; Shantou, China · 39 sites in all
- Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic EczemaPivotal-lookingNot yet recruiting
Jinnah Postgraduate Medical CentreGovernment (non-federal)
NCT07438509 · 270 participants (planned) · Start Mar 1, 2026 · Primary completion Sep 1, 2026
Drug: Placebo Cream; Crisaborole 2% Cream · For: Atopic Dermatitis (AD); Atopic Eczema
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate ADPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT03539601 · 237 participants · Start Apr 27, 2018 · Primary completion Dec 11, 2020
Drug: Crisaborole ointment, 2%; Hydrocortisone butyrate cream, 0.1% and 2 more · For: Atopic Dermatitis
Sites: Bryant, Arkansas; Encinitas, California; Orange Park, Florida · 32 sites in all
Massachusetts General HospitalAcademic, hospital or other
NCT04214197 · 150 participants (planned) · Start Feb 3, 2020 · Primary completion Jul 2021
Drug: Crisaborole 2% Top Oint · For: Atopic Dermatitis
Sites: Boston, Massachusetts
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic DermatitisPivotal-lookingNot yet recruiting
Hayat Abad Medical Complex, PeshawarGovernment (non-federal)
NCT07437534 · 148 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 25, 2026
Drug: Crisaborole 2% Topical Application Ointment [EUCRISA; tacrolimus 0.1% · For: Atopic Dermatitis
Sites: Peshawar, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,995
- application site pain1,417
- burning sensation987
- off label use759
- condition aggravated711
- pruritus662
- rash622
- pain530
- eczema469
- dermatitis atopic455
- erythema376
- product use in unapproved indication341
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1,288 |
| 2018 | 2,074 |
| 2019 | 1,981 |
| 2020 | 1,051 |
| 2021 | 497 |
| 2022 | 941 |
| 2023 | 675 |
| 2024 | 528 |
| 2025 | 371 |
| 2026 | 197 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eucrisa (Crisaborole)
2024 spending
$9.3M
Beneficiaries
4,837
10,592 claims
Per beneficiary
$1,918
$11.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,052,208 |
| 2021 | $11,744,648 |
| 2022 | $10,566,575 |
| 2023 | $10,407,692 |
| 2024 | $9,279,367 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Clin Exp Allergy 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, Tom WL, Lebwohl MG, et al. · J Am Acad Dermatol 2016 · Clinical Trial, Phase III, Randomized Controlled Trial
- Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
Stein Gold LF, Tom WL, Shi V, et al. · Dermatitis 2024 · Randomized Controlled Trial
- Pharmacological management of atopic dermatitis in the elderly.
Howell AN, Ghamrawi RI, Strowd LC, et al. · Expert Opin Pharmacother 2020 · Systematic Review
Sponsor: Anacor Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.